Following promising pre-clinical studies, the FAK inhibitor PF-562271 was the first FAK inhibitor to enter clinical trials in solid tumours including, pancreatic, head and neck, and prostate cancer (NCT00666926), with one-third of patients showing disease stabilisation [34,78,79]. Here, PTK2 is linked to prostate cancer.